glp-1 news today 2025 october 9 Regulating a "Miracle Drug": Costs, Access, & Safety GLP-1 Spending Hit $5.8 Billion

Flynn and Dooley, 2021)

Tirzepatide was FDA-approved in 2023 specifically for weight loss in people without diabetes, making it a transformative option for millions seeking sustainable weight management

ET on October 30, 2025 For most of my adult life, Ive felt helpless about being overweight

Injections, being quick and requiring fewer sessions, might better suit a busy lifestyle

(2000) Extensive polymorphism in Cryptosporidium parvum identified by multilocus microsatellite analysis Appl

The approval is the second for Krazati, which is also FDA-authorized to treat KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer